Literature DB >> 7707316

Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines.

P J Garratt1, R Jones, D A Tocher, D Sugden.   

Abstract

Three series of 2-phenyltryptamides were prepared as melatonin analogues to investigate the nature of the binding site of the melatonin receptor in chicken brain and in Xenopus laevis melanophore cells. The 5-methoxy-2-phenyltryptamides (6a-j) have high binding affinities for the chicken brain receptor, in some cases (6a-d) greater than that for melatonin, confirming and extending the work of Spadoni et al., and act as agonists in the Xenopus melanophore assay. Analogues lacking the 5-methoxyl group (2a-n) had a considerably lower affinity for the chicken brain receptor. In the Xenopus melanophore assay the compounds acylated on nitrogen by an alkyl group (2a-d) were agonists whereas the compounds acylated on nitrogen by an alicyclic group (2f-i) were antagonists. Introducing a methyl group at N1 (7) led to an increase in binding affinity in the chicken brain assay, whereas introducing an ethyl group (13) led to a decrease in binding affinity. A methyl substituent at the beta-position of the 3-amidoethane side chain (8, 11) also led to an increase in the binding affinity. The only analogue acylated on nitrogen with an alkyl group (acetyl) which showed antagonist activity was 9, which has a beta-methoxymethyl side chain. In the absence of the 5-methoxyl group the methoxymethyl function may cause the molecule to bind in a different configuration so that it is no longer able to activate the receptor. All of these observations are in agreement with a model of melatonin at the receptor site in which the 3-amidoethane side chain is in a conformation close to the 5-methoxyl group.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707316     DOI: 10.1021/jm00007a010

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists.

Authors:  R Nonno; M Pannacci; V Lucini; D Angeloni; F Fraschini; B M Stankov
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and Xenopus melanophores.

Authors:  H Pickering; S Sword; S Vonhoff; R Jones; D Sugden
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

4.  The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

5.  Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus).

Authors:  Célia Gautier; Sophie-Penelope Guenin; Isabelle Riest-Fery; Tahlia Jade Perry; Céline Legros; Olivier Nosjean; Valerie Simonneaux; Frank Grützner; Jean A Boutin
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

6.  Exogenous Melatonin Activating Nuclear Factor E2-Related Factor 2 (Nrf2) Pathway via Melatonin Receptor to Reduce Oxidative Stress and Apoptosis in Antler Mesenchymal Stem Cells.

Authors:  Huansong Jing; Xuyang Sun; Mengqi Li; Jingna Peng; Xiaoying Gu; Jiajun Xiong
Journal:  Molecules       Date:  2022-04-13       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.